Literature DB >> 3107462

Norfloxacin versus thiamphenicol for treatment of uncomplicated gonorrhea in Rwanda.

J Bogaerts, W Martinez Tello, L Verbist, P Piot, J Vandepitte.   

Abstract

In an open prospective study, single oral doses of norfloxacin (800 mg) and thiamphenicol (2.5 g) were used to treat, respectively, 122 and 46 consecutive patients with uncomplicated gonorrhea. Neisseria gonorrhoeae was eradicated from 119 (97.5%) patients treated with norfloxacin and from 35 (76.0%) patients treated with thiamphenicol. Norfloxacin treatment failure was not related to drug resistance or to insufficient absorption of the drug. Thiamphenicol failure correlated with low in vitro susceptibility of the infecting strain. In a single oral dose of 800 mg, norfloxacin appeared to be an excellent alternative treatment regimen for uncomplicated gonorrhea in an area with a high prevalence of penicillin-resistant gonococci.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107462      PMCID: PMC174746          DOI: 10.1128/AAC.31.3.434

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  A double blind study comparing two dosages of enoxacin for the treatment of uncomplicated urogenital gonorrhoea.

Authors:  A Notowicz; E Stolz; B van Klingeren
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

2.  Comparison of spectinomycin, cefuroxime, thiamphenicol, and penicillin G in the treatment of uncomplicated gonococcal infections in women.

Authors:  T Tupasi; L B Crisologo; C A Torres; O V Calubiran
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

3.  Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.

Authors:  M Y Khan; Y Siddiqui; R P Gruninger
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

4.  In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.

Authors:  M Peeters; E Van Dyck; P Piot
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

5.  Rosoxacin in the therapy of uncomplicated gonorrhea.

Authors:  B Romanowski; T W Austin; F L Pattison; D Lawee; D Portnoy; K F Givan; E L Li; K B Nguyen
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

6.  Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin.

Authors:  S R Crider; S D Colby; L K Miller; W O Harrison; S B Kerbs; S W Berg
Journal:  N Engl J Med       Date:  1984-07-19       Impact factor: 91.245

7.  Treatment of uncomplicated gonorrhea with rosoxacin.

Authors:  H H Handsfield; F N Judson; K K Holmes
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

8.  Comparison of thiamphenicol and spectinomycin in the treatment of uncomplicated gonorrhea in men.

Authors:  J H Kim
Journal:  Sex Transm Dis       Date:  1984 Oct-Dec       Impact factor: 2.830

9.  Treatment of gonorrhea with single-dose thiamphenicol in Kenya.

Authors:  H Nsanze; L J D'Costa; D M Owili; F Ilako; P Piot
Journal:  Sex Transm Dis       Date:  1984 Oct-Dec       Impact factor: 2.830

10.  "One-minute treatment" with thiamphenicol in 50,000 cases of gonorrhea: a 22-year study.

Authors:  A Siboulet; J M Bohbot; N Lhuillier; A Siboulet; F Catalan
Journal:  Sex Transm Dis       Date:  1984 Oct-Dec       Impact factor: 2.830

  10 in total
  6 in total

Review 1.  Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

2.  In vitro activity and mode of action of fluoroquinolones.

Authors:  L Verbist
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

3.  Characterization, in vitro susceptibility, and clinical significance of CDC group HB-5 from Rwanda.

Authors:  J Bogaerts; J Verhaegen; W Martinez Tello; S Allen; L Verbist; E Van Dyck; P Piot
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

4.  Effectiveness of norfloxacin and ofloxacin for treatment of gonorrhoea and decrease of in vitro susceptibility to quinolones over time in Rwanda.

Authors:  J Bogaerts; W M Tello; J Akingeneye; V Mukantabana; E Van Dyck; P Piot
Journal:  Genitourin Med       Date:  1993-06

Review 5.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

6.  Comparative in vitro activity of norfloxacin against resistant Neisseria gonorrhoeae.

Authors:  S Ponticas; D L Shungu; C J Gill
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.